CDC Updates Its Childhood Obesity Facts

Last week, the Centers for Disease Control and Prevention (CDC) released its childhood obesity facts, updated with some recent research data. While there are no shocking revelations to be glimpsed, especially by the readers of this blog, it’s always useful to try seeing the big picture backed up by reliable research. The numbers reveal a growing issue that touches nearly every part of society. No big surprise there, either. Here are some highlights (or, shall we say, lowlights).

Obesity in numbers

Between 2017 and March 2020, obesity affected 19.7% of children and adolescents in the United States. That translates to approximately 14.7 million young people between the ages of 2 and 19. For children, obesity is measured using Body Mass Index (BMI), with obesity defined as having a BMI at or above the 95th percentile for a child’s age and sex.

The climbing rates

One of the most concerning trends is how obesity rates increase as children get older. Among children ages 2 to 5, the obesity rate was 12.7%. However, the percentage climbed significantly among older age groups, reaching 20.7% for children ages 6 to 11 and 22.2% for adolescents ages 12 to 19. These statistics suggest that unhealthy habits and lifestyle challenges may intensify as children grow older, making early intervention especially important.

Racial and ethnic disparities

The data also highlights major disparities among racial and ethnic groups. Hispanic children experienced the highest obesity prevalence at 26.2%, followed closely by non-Hispanic Black children at 24.8%. In comparison, obesity rates were 16.6% among non-Hispanic white children and 9.0% among non-Hispanic Asian children. These differences point to broader social and environmental factors that can influence access to nutritious food, safe places to exercise, healthcare resources, and education about healthy living.

Obesity by gender

Gender differences also appear within these statistics. Among girls, obesity rates were highest in non-Hispanic Black girls, with nearly one-third affected. Among boys, Hispanic boys experienced the highest obesity prevalence at 29.3%. These patterns demonstrate that childhood obesity does not affect all groups equally and that targeted community-based solutions may be necessary.

Family income

Family income plays a significant role as well. Children from lower-income households were more likely to experience obesity than those from higher-income families. Obesity affected 25.8% of children living at or below 130% of the Federal Poverty Level, compared to just 11.5% of children from families earning more than 350% of the poverty level. Financial limitations can make it harder for families to purchase healthier foods, participate in recreational activities, or access preventive healthcare services.

Healthcare costs

Beyond the physical health concerns, childhood obesity also creates a major financial burden. Healthcare costs related to obesity among U.S. children reached an estimated $1.3 billion annually in 2019 dollars. On average, children with obesity incurred $116 more in medical expenses each year compared to children with healthy weight. For children with severe obesity, those costs rose to $310 more per year. These expenses reflect increased medical visits, treatments, and long-term health risks associated with obesity-related conditions.

It takes a village

Addressing childhood obesity requires a collaborative effort from families, schools, healthcare systems, and policymakers. Encouraging healthy eating habits, increasing opportunities for physical activity, improving access to affordable nutritious foods, and supporting preventive healthcare can all play a role in reducing obesity rates. While the statistics are serious, they also provide an opportunity to focus on meaningful solutions that can improve the health and well-being of future generations.

Your responses and feedback are welcome!

Source: “Childhood Obesity Facts,” CDC, 5/6/26
Source: “National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes,” National Health Statistics Report, 2021
Source: “Association of body mass index with health care expenditures in the United States by age and sex,” PLOS One, 3/24/21
Image by U.S. Centers for Disease Control and Prevention, via Wikimedia Commons/Public Domain

GLP-1 Coverage Cuts by Medicaid

As demand for GLP-1 medications continues to surge across the United States, a growing number of states are reevaluating whether they can afford to cover these drugs for obesity treatment under Medicaid. Recent proposals in Massachusetts and Rhode Island highlight a broader national trend: balancing access to innovative but expensive therapies with the realities of state budgets.

A shrinking list of states offering coverage

Just a year ago, 16 state Medicaid programs covered GLP-1 medications specifically for weight loss. That number has now dropped to 13. States like California, New Hampshire, Pennsylvania, and South Carolina have already eliminated this benefit, citing unsustainable costs.

GLP-1 drugs, originally developed for diabetes management, have gained widespread attention for their effectiveness in promoting weight loss. However, their high price tag has made them a significant financial burden for publicly funded programs like Medicaid.

Proposed changes in Massachusetts and Rhode Island

In Massachusetts, Governor Maura Healey’s proposed fiscal 2028 budget would remove coverage of GLP-1 drugs for weight loss under MassHealth, the state’s Medicaid program. Importantly, coverage would remain intact for patients using these medications to treat diabetes or other medical conditions. The proposal is still under legislative review, leaving room for potential revisions.

Similarly, Rhode Island’s governor has proposed eliminating Medicaid coverage for GLP-1 medications when prescribed solely for obesity treatment. These decisions reflect a growing concern among policymakers: how to prioritize limited healthcare dollars while still addressing widespread chronic conditions.

Despite these cutbacks, several states continue to provide coverage for GLP-1 drugs for obesity. These include Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, Tennessee, Utah, Virginia, and Wisconsin.

However, even among these states, access is often limited. For example, Michigan has restricted eligibility to patients with morbid obesity, excluding those who are overweight or moderately obese. This policy adjustment alone is projected to save the state an estimated $240 million, illustrating the scale of financial pressure these medications create.

Louisiana’s ongoing debate

In Louisiana, lawmakers are considering a middle-ground approach. Rather than offering broad coverage, the state may allow Medicaid to cover GLP-1 medications for obesity only when patients also have a related chronic condition, such as prediabetes, hypertension, or cardiovascular disease.

This strategy aims to target patients at the highest risk while controlling costs, but it also raises questions about equity and early intervention. Should treatment be limited to those already experiencing complications, or should it be expanded to prevent them?

The cost challenge

The financial strain driving these decisions is substantial. Medicaid spending on GLP-1 prescriptions (covering both diabetes and weight loss) has skyrocketed from about $1 billion in 2019 to nearly $9 billion in 2024, according to KFF.

For those without insurance, affordability remains a major barrier. In response, Novo Nordisk announced plans to lower the list price of its GLP-1 medications to $675 per month by 2027. While this reduction may improve access, it is still a significant expense for many patients and for state-funded programs.

High need, limited access

The debate over GLP-1 coverage comes at a time when obesity rates remain high. Nearly 40% of adults and about 25% of children enrolled in Medicaid have obesity, suggesting a large population could potentially benefit from these medications. Yet, as states tighten coverage, a pattern emerges: Innovative treatments are becoming more effective and more popular, but not necessarily more accessible.

The kids are also affected

As Philadelphia’s WHYY reported, the Children’s Hospital of Philadelphia (CHOP) did some research about the coverage specifically for children:

CHOP researchers found that only a fraction of eligible kids ultimately get a GLP-1 prescription. Even after they do, families struggle with cost and insurance coverage issues that make it hard for their children to stay on the medication.

Side effects and gaps in follow-up care are also causing disruptions in medication use, according to CHOP’s findings, recently published in the journal Pediatrics.

Looking ahead

The future of GLP-1 coverage under Medicaid is far from settled. As more states weigh the costs and benefits, policies will likely continue to evolve, creating a patchwork system where access depends heavily on geography.

For patients, providers, and policymakers alike, the challenge is clear: how to expand access to life-changing treatments without overwhelming already stretched healthcare budgets. Whether through pricing reforms, eligibility adjustments, or alternative treatment strategies, the decisions made today will shape obesity care for years to come.

Your responses and feedback are welcome!

Source: “Philly pediatricians are using GLP-1 drugs to treat childhood obesity, but cost can be a major barrier, CHOP doctors find,” WHYY, 5/4/26
Source: “Only 13 States’s Medicaid Still Cover GLP-1 Drugs to Treat Obesity, and More Are Dropping Out,” FlaglerLive.com, 4/30/26
Source: “Rhode Island considers ending Medicaid coverage of GLP-1 drugs for weight loss,” Rhode Island Current, 6/10/25
Source: “Louisiana Medicaid might add coverage for popular obesity treatment drugs,” Louisiana Illuminator, 4/16/26
Source: “Medicaid Coverage of and Spending on GLP-1s,” KFF, 1/16/26
Image by SHVETS production/Pexels

What New Research Says About Childhood Growth and BMI

For decades, pediatric health experts have relied on a concept known as “adiposity rebound” to help assess a child’s future risk of obesity. Traditionally, this stage, when body mass index (BMI) begins to rise again after early childhood, has been viewed as a potential warning sign. But new research published in The Journal of Nutrition is challenging that long-held belief and offering a more nuanced understanding of how children grow.

A look at childhood growth patterns

The study analyzed data from 2,410 children and adolescents ages 2 to 19 who participated in the National Health and Nutrition Examination Survey (NHANES) between 2021 and 2023. Researchers observed a familiar trend: BMI decreases in early childhood, then begins to rise again around age 6 — the classic “adiposity rebound.”

However, there was a surprising twist. While BMI increased, another important measurement, the waist-to-height ratio, continued to decline. This metric is considered a more accurate indicator of body fat, particularly abdominal fat.

The implication? The rise in BMI during this stage may not signal increased fat at all. Instead, it may reflect healthy growth in lean tissues like muscle and bone.

Why BMI alone may be misleading

BMI has long been used as a simple screening tool because it relies on such basic measurements as height and weight. But it has a significant limitation, as it cannot distinguish between fat mass and fat-free mass. This distinction is especially important in children, whose bodies are constantly changing.

Lead researcher Andrew Agbaje emphasized this concern, saying:

Recent global consensus statements on redefining and diagnosing obesity have recommended that obesity should not be diagnosed with BMI alone but confirmed with non-invasive measures such as waist-to-height ratio.

He also said:

This new study buttresses the misleading use of BMI in children whose body composition rapidly changes during growth and the potential for attributing physiological functions to pathology, which might lead to unnecessary interventions. Waist-to-height ratio should be incorporated as the first inexpensive measure in diagnosing pediatric obesity with BMI used as a confirmatory tool due to its imprecision.

Introducing the “body composition reset”

One of the most compelling ideas to emerge from the study is what researchers call a “body composition reset.” This term describes the natural shift toward lean tissue development during early childhood. Rather than indicating a buildup of fat, the increase in BMI may actually reflect a healthy phase of growth, one that supports strength, bone development, and overall physical maturation. This finding challenges the assumption that an earlier adiposity rebound automatically signals a higher risk of obesity later in life.

Why waist-to-height ratio matters

Unlike BMI, the waist-to-height ratio focuses on fat distribution, particularly abdominal fat, which is more closely linked to health risks such as heart disease, Type 2 diabetes, high blood pressure, liver disease, and bone fractures. Because it is less influenced by muscle growth, this measurement provides a clearer picture of whether a child is carrying excess body fat.

A shift in pediatric obesity screening

The study adds to a growing body of evidence suggesting that BMI should not be used in isolation when evaluating children’s health. Incorporating waist-to-height ratio could help clinicians better distinguish between normal growth and true obesity risk, avoid unnecessary labeling or interventions, and provide more accurate, individualized care, among other things.

Recognition for innovative research

Agbaje’s contributions to pediatric cardiometabolic health have not gone unnoticed. He is the inaugural recipient of the American Society for Nutrition Foundation/Novo Nordisk Foundation Flemming Quaade Award, which honors early-career physicians making significant strides in obesity prevention and management. The award will be presented again at NUTRITION 2026, scheduled for July 25–28, 2026, in National Harbor, Maryland.

So, in a nutshell, a single number like BMI cannot tell the whole story. The new approach may reduce the chances of misclassifying healthy developmental changes as medical concerns. For parents, it should serve as a reassuring message that not every change in BMI signals a problem. Sometimes, it simply reflects a child growing exactly as they should.

Your responses and feedback are welcome!

Source: “Study Challenges Decades-Old Puzzle About Childhood Body Fat,” American Society for Nutrition, 4/23/26
Source: “Adiposity Rebound or Fat-Free Mass Anabolism in Children…,” The Journal of Nutrition, 3/9/26
Image by beyzahzah/Pexels

Genetics May Shape the Future of GLP-1 Medications

Childhood obesity treatment is entering a new and highly personalized era. As GLP-1 receptor agonists gain traction as effective tools for weight management in adolescents, emerging research suggests that genetics may play a key role in determining who benefits most (and who experiences side effects).

This evolving intersection of obesity medicine and precision health could transform how providers treat pediatric patients. But it also raises important questions about cost, access, and equity.

The rise of GLP-1 medications in pediatric care

GLP-1 (glucagon-like peptide-1) receptor agonists, including semaglutide and liraglutide, have rapidly become a cornerstone of modern obesity treatment. Originally developed for type 2 diabetes, these medications help regulate appetite, slow digestion, and improve blood sugar control. In adolescents with obesity, clinical trials have demonstrated significant reductions in body mass index (BMI), often far exceeding results from lifestyle interventions alone.

A major study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16% reduction in BMI over 68 weeks. These results have fueled growing adoption in pediatric care and prompted updated treatment guidelines from the American Academy of Pediatrics, which now include pharmacotherapy as part of comprehensive obesity management.

While GLP-1 medications have shown impressive results, not all patients respond the same way. Some adolescents lose significant weight, while others see more modest changes, or struggle with side effects like nausea and vomiting. Recent research highlights a possible explanation: genetic variation. Studies suggest that certain genetic differences may influence how the body regulates appetite and metabolism, how strongly GLP-1 receptors respond to medication, and the likelihood and severity of gastrointestinal side effects.

In fact, new findings reported by Reuters indicate that specific genetic markers may be linked to both greater weight loss outcomes and increased side effect risk in patients taking GLP-1 drugs. This opens the door to a more tailored approach, where treatment decisions are guided not just by BMI or medical history, but by a patient’s genetic profile.

What is personalized (precision) medicine?

Personalized medicine, also known as precision medicine, is an approach that uses individual factors like genetics, environment, and lifestyle to guide healthcare decisions. The National Institutes of Health defines precision medicine as a way to “optimize medical care by tailoring it to individual characteristics.”

In the context of pediatric obesity, this could mean identifying which children are most likely to benefit from GLP-1 medications, predicting who may experience side effects before treatment begins, and adjusting dosages or selecting alternative therapies based on genetic insights. This approach has the potential to make treatment more effective, safer, and more efficient.

Potential benefits for pediatric patients

If successfully implemented, genetically guided obesity treatment could offer several advantages:

1. Improved Outcomes. Children could receive medications that are more likely to work for their specific biology, increasing the chances of meaningful weight loss and improved health.
2. Reduced Trial-and-Error. Providers could avoid prescribing medications that are less likely to be effective, saving time and reducing frustration for families.
3. Better Side Effect Management. Identifying genetic risk factors for side effects may help clinicians proactively manage or avoid adverse reactions.
4. More Efficient Use of Healthcare Resources. Targeted treatment could reduce unnecessary costs associated with ineffective therapies.

Ethical and equity considerations

While the promise of personalized medicine is compelling, it also introduces new challenges, particularly around access and equity, such as cost barriers, a risk of widening disparities, and data privacy concerns. Genetic testing can be expensive, and insurance coverage is inconsistent. Combined with the already high cost of GLP-1 medications, this could limit access for many families.

Also, communities already disproportionately affected by childhood obesity, such as low-income and minority populations, may have the least access to advanced testing and treatments. And, the Centers for Disease Control and Prevention continues to report higher obesity rates among underserved populations, making equitable access a critical concern. Plus, genetic testing raises questions about how sensitive health data is stored, shared, and protected (especially for children).

The integration of genetics into pediatric obesity treatment represents a major step toward more individualized, science-driven care. However, experts emphasize that medication, personalized or not, should always be part of a broader, holistic approach.

As research continues, the key challenge will be ensuring that innovation does not outpace accessibility. Personalized treatment has the potential to improve outcomes, but only if it is available to all children who need it.

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Semaglutide Treatment Effect in People With Obesity — STEP TEENS,” American College of Cardiology, 12/20/22
Source: “Genetics may help explain why results from weight-loss jabs vary, say scientists,” The Guardian, 4/6/26
Source: “Researchers move closer to matching patients with GLP-1 drug that works best for them,” Reuters, 11/19/25
Source: “The Promise of Precision Medicine,” NIH, undated
Source: “New CDC Data Show Adult Obesity Prevalence Remains High,” CDC, 9/12/24
Image by Tara Winstead/Pexels

The Rise of GLP-1 Medications in Pediatric Obesity: Breakthrough or Barrier?

Childhood obesity remains one of the most urgent public health challenges in the United States, affecting roughly one in five children and adolescents. According to the Centers for Disease Control and Prevention, the prevalence of obesity among U.S. youth is about 19.7%, with higher rates among certain racial, ethnic, and low-income populations.

While lifestyle interventions, such as improved nutrition, increased physical activity, and behavioral counseling, have long been the foundation of treatment, a new class of medications is rapidly transforming the field: GLP-1 receptor agonists. These drugs are generating both excitement and debate, especially as their use expands into pediatric care.

So, are GLP-1 medications a true breakthrough, or do they risk widening existing gaps in care?

What are GLP-1 medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a naturally-occurring hormone involved in regulating appetite, insulin secretion, and digestion. By slowing gastric emptying and increasing satiety, they help reduce food intake and promote weight loss.

Two of the most widely discussed GLP-1 medications are semaglutide and liraglutide. Originally approved for type 2 diabetes, both medications are now FDA-approved for chronic weight management in certain adolescent populations aged 12 and older. Their growing popularity reflects a broader shift toward recognizing obesity as a chronic, biologically complex disease, not simply a result of lifestyle choices.

Clinical trials have demonstrated significant results in adolescents using GLP-1 medications. A landmark study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16.1% reduction in BMI, compared to just 0.6% in the placebo group. Similarly, trials involving liraglutide showed meaningful reductions in BMI and improvements in metabolic health markers.

Beyond weight loss, GLP-1 medications may improve insulin resistance, blood pressure, and lipid profiles (cholesterol levels). These benefits are particularly important given that childhood obesity is strongly linked to long-term risks such as type 2 diabetes, cardiovascular disease, and even certain cancers.

Despite their clinical promise, GLP-1 medications remain out of reach for many families. Without insurance, these drugs can cost $900 to $1,300 per month, a significant financial burden. Even for insured patients, access is often delayed by prior authorization requirements, step therapy protocols, and inconsistent coverage policies.

According to the American Academy of Pediatrics, disparities in access to obesity treatment, including medications, mirror broader inequities in healthcare. Children from underserved communities, who are already at higher risk for obesity, are often the least likely to receive advanced treatments.

Additional barriers include limited availability of pediatric obesity specialists, geographic disparities in care access, and stigma surrounding obesity treatment. This raises a critical concern: Could a breakthrough therapy unintentionally widen health disparities?

While short-term outcomes are encouraging, long-term safety data in pediatric populations is still evolving.

Common side effects include nausea, vomiting, diarrhea, or constipation. In most cases, these symptoms are mild to moderate and improve over time. However, there are still unanswered questions about long-term use in developing bodies, potential impacts on growth and development, weight regain after discontinuation, and more.

Early evidence suggests that stopping GLP-1 therapy often leads to partial or full weight regain, highlighting the chronic nature of obesity and the potential need for ongoing treatment. Experts emphasize that medication should not replace foundational lifestyle interventions but instead serve as part of a comprehensive, multidisciplinary care plan.

The emergence of GLP-1 medications marks a turning point in pediatric obesity treatment. For adolescents who have struggled with traditional approaches, these therapies offer meaningful, evidence-based results, and in many cases, renewed hope. However, their full potential will only be realized if systemic barriers are addressed.

Expanding insurance coverage, improving provider access, and reducing stigma will be essential to ensuring equitable care. As research continues and policies evolve, the challenge is clear: How do we ensure that this medical breakthrough benefits all children, not just a select few?

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023,” CDC, 6/5/25
Source: “Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics, February 2023
Source: “New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth,” ICER, 10/23/25
Image by Leeloo The First/Pexels

How Childhood Obesity May Be Reshaping the American Dream

For generations, the idea of the American Dream has rested on a simple promise: Every child has the opportunity to build a better life than their parents. But emerging research from Rutgers suggests that a growing health crisis of childhood obesity may be quietly undermining that promise in ways that extend far beyond physical well-being.

Childhood obesity has long been associated with increased risks of chronic conditions like diabetes, heart disease, and mental health challenges. Now, a new study published in the Journal of Population Economics reveals that its impact may also stretch into lifetime earnings and financial mobility.

According to the research, children who experience obesity are significantly less likely to climb the economic ladder as adults. In fact, their income ranking can fall about 20 percentile points below that of their parents, compared to peers who maintained a healthy weight in childhood.

As study co-author Dr. Yanhong Jin explains,

Childhood obesity isn’t just a health crisis — it is an economic mobility crisis.

The study draws on data from the National Longitudinal Study of Adolescent to Adult Health, a large-scale, long-running dataset that has tracked more than 20,000 Americans from adolescence into adulthood over several decades. This rich dataset allowed researchers to examine not only health outcomes, but also education, income, and even genetic factors tied to body weight.

By incorporating genetic data, the researchers were able to isolate the effects of obesity itself, separate from influences such as family income or neighborhood environment. The findings were striking: Even when controlling for these factors, childhood obesity remained strongly linked to lower economic mobility.

The study highlights several key reasons why children with obesity may face economic disadvantages later in life. One is lower educational attainment. Children with obesity may encounter barriers in school, from absenteeism to social stigma, which can impact academic success.

Then there are ongoing health challenges. Chronic health conditions can limit productivity, career choices, and long-term earning potential. Also, think about the workplace disadvantages. Adults who were obese as children reported higher levels of job discrimination and were more likely to end up in lower-paying occupations.

Together, these factors create a compounding effect that can make it harder to achieve upward mobility.

Where you grow up also matters. The research also found that individuals who experienced childhood obesity were less likely to live in economically thriving neighborhoods as adults. They were more likely to reside in areas with lower average incomes and higher poverty rates, further limiting access to opportunity.

Interestingly, the economic impact of childhood obesity was not evenly distributed. Girls experienced a larger economic penalty than boys. Not surprisingly, children from low-income families were more affected. And those raised in the South and Midwest faced stronger long-term impacts. These disparities suggest that childhood obesity may amplify existing inequalities, making it even harder for vulnerable populations to break cycles of poverty.

Traditionally, efforts to address obesity have focused on treatment, helping people lose weight after the condition develops. But this research points to the importance of early prevention.

Intervening during childhood — before obesity takes hold — could yield benefits that go far beyond improved health. It may also enhance educational outcomes, expand career opportunities, and increase the likelihood of upward mobility.

As co-author Man Zhang notes, tackling childhood obesity isn’t just about reducing healthcare costs. It’s about investing in the future economic potential of the next generation.

This study challenges us to think differently about childhood obesity. It is not only a medical issue or a lifestyle concern — it is also a social and economic one.

As science writer and researcher Sanjana Gajbhiye writes for Earth.com,

Preventing obesity early can improve both health and future opportunities. It can support better education, stronger careers, and higher income levels.

Protecting the promise of the American Dream may require expanding how we view public health challenges and recognizing that the well-being of children today is deeply connected to the economic vitality of tomorrow.

Your responses and feedback are welcome!

Source: “Childhood Obesity Makes It Harder to Climb the Economic Ladder, Study Finds,” Rutgers.edu, 3/18/26
Source: “Childhood obesity may lower a child’s chances of moving up in life,” Earth.com, 3/19/26
Image by Towfiqu barbhuiya/Pexels